FLT3 and acute myeloid leukemia: Preclinical studies in AML with the combination of vorinostat and AZD-1775 have shown striking synergism, irrespective of p53 and FLT3 mutational status, including in “LIC”s, primary AML blasts and in a xenograft mouse (flank) model [128].